|Day Low/High||0.95 / 1.04|
|52 Wk Low/High||1.91 / 7.93|
Data suggests safety and potential sustained efficacy in post prostatectomy patients failing pharmacologic intervention
Cytori Therapeutics stock is sinking after the biotech company priced a stock offering at steep discount.
Presentation on February 15, 2017 at 11:15 AM Eastern Time
Here's how biotech and healthcare stocks are moving ahead of market's open.
Presentation on January 10, 2016 at 4:00 PM Pacific Time
Cytori Therapeutics, Inc. (NASDAQ: CYTX) ("Cytori" or the "Company") announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for cryopreserved or centrally processed ECCS-50 for...
Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its third quarter financial results and provided updates on its corporate activity and clinical development.
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present new preclinical data describing positive effects of Cytori Cell Therapy™ on a corneal wound healing model and in cutaneous scarring following burn injury.